Concepedia

Thomas Nittoli

TN

Statistics

Publications

16

Citations

925

H-Index

14

Active since

1998

Affiliations

Pearl River Community College(Current)

Regeneron (United States)

Pfizer (United States)

State University of New York

Stony Brook University

Thomas Nittoli is an author at Pearl River Community College specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

1998–2021

16

Publications

16

Silicon-Based Metalloprotease Inhibitors:  Synthesis and Evaluation of Silanol and Silanediol Peptide Analogues as Inhibitors of Angiotensin-Converting Enzyme<sup>1</sup>

Mwangi wa Mutahi, Thomas Nittoli, Luxuan Guo et al. · Journal of the American Chemical Society · 2002 · 196 citations

, , +13

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

Julian Andreev, Nithya Thambi, Andrés E. Perez Bay et al. · Molecular Cancer Therapeutics · 2017 · 164 citations

, , +17

Silanediols: A New Class of Potent Protease Inhibitors

Scott McN. Sieburth, Thomas Nittoli, Alfred M. Mutahi et al. · Angewandte Chemie International Edition · 1998 · 136 citations

, , +17

Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2

Allan Wissner, Heidi L. Fraser, Charles L. Ingalls et al. · Bioorganic & Medicinal Chemistry · 2007 · 75 citations · Full text

, , +14

2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as Covalent-Binding, Irreversible Inhibitors of the Kinase Domain of Vascular Endothelial Growth Factor Receptor-2

Allan Wissner, M. Brawner Floyd, Bernard D. Johnson et al. · Journal of Medicinal Chemistry · 2005 · 57 citations · Full text

, , +15

1–5 of 16